Showing results (701-710 of 772) with videos related to
Sort By:
Pageof 78
Clinical Pharmacology and Therapeutics|January 22, 2022
Translational Approaches for Brain Delivery of Biologics via Cerebrospinal FluidShraddha S Sadekar, Mayumi Bowen, Hao Cai, et al.Resuscitation|August 10, 2017
Potential impact of a prehospital redirection system for refractory cardiac arrestAlexis Cournoyer, Éric Notebaert, Luc de Montigny, et al.Journal of Medicinal Chemistry|July 28, 2009
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophreniaPatrick R Verhoest, Douglas S Chapin, Michael Corman, et al.Seminars in Arthritis and Rheumatism|August 31, 2021
Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort studyColin R Dormuth, Anat Fisher, Marie Hudson, et al.Scientific Data|March 5, 2026
Proteomic profiling of human omental and subcutaneous adipose tissue in individuals with a broad range of BMIAlex Zelter, Yue Winnie Wen, Michael Riffle, et al.Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.Epilepsia|October 10, 2024
One-year follow-up of neurobehavioral therapy in functional seizures or epilepsy with traumatic brain injury: A nonrandomized controlled trialRyan Van Patten, Andrew Blum, Stephen Correia, et al.Journal of Cell Science|September 4, 2016
Neuropilin-1 modulates interferon-γ-stimulated signaling in brain microvascular endothelial cellsYing Wang, Ying Cao, Ashutosh K Mangalam, et al.Scientific Reports|November 15, 2018
Calpain-mediated tau fragmentation is altered in Alzheimer's disease progressionHsu-Hsin Chen, Peter Liu, Paul Auger, et al.Mabs|April 16, 2019
An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humansShan Chung, Van Nguyen, Yuwen Linda Lin, et al.Pageof 78